Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/Allisartan and Amlodipine in Essential Hypertension Uncontrolled With Amlodipine
NCT07704684Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
A Phase 3 trial of sacubitril + valsartan in essential hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Jun 2023; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT07704684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07704684.